Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GeneDx Holdings Corp.WGS · Entity 1634 | Director | June 18, 2026 | June 23, 2026 |
| Twist Bioscience CorpTWST · Entity 3619 | Director · Chief Executive Officer | October 05, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GeneDx Holdings Corp.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 24,852 |
Reported balance
After 2026-06-18 transaction · row 1
1 source rowRow 1 · 2026-06-18 · Exercise / conversion · Acquired 3,576 · Balance 24,852 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 4,248 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Grant · Acquired 4,248 · Balance 4,248 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2: The entire award shall vest on the earlier of the (i) date of the 2027 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-18 · Exercise / conversion · Disposed 3,576 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3: The entire award vested or vests on the earlier of the: (i) date of the 2026 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
F2: The entire award shall vest on the earlier of the (i) date of the 2027 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.
F3: The entire award vested or vests on the earlier of the: (i) date of the 2026 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.
Twist Bioscience Corp
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 562,760 |
Ending reported balance
After 2026-10-05 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2026-10-05 · Sale · Disposed 1,840 · Balance 565,468 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F2: Represents the weighted average sales price per share. The shares sold at prices ranging from $200 to $200.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 2 · 2026-10-05 · Sale · Disposed 481 · Balance 564,987 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F3: Represents the weighted average sales price per share. The shares sold at prices ranging from $201 to $201.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 3 · 2026-10-05 · Sale · Disposed 1,017 · Balance 563,970 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F4: Represents the weighted average sales price per share. The shares sold at prices ranging from $202 to $202.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 4 · 2026-10-05 · Sale · Disposed 432 · Balance 563,538 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F5: Represents the weighted average sales price per share. The shares sold at prices ranging from $203.29 to $203.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 5 · 2026-10-05 · Sale · Disposed 290 · Balance 563,248 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F6: Represents the weighted average sales price per share. The shares sold at prices ranging from $204.33 to $205.32 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 6 · 2026-10-05 · Sale · Disposed 297 · Balance 562,951 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F7: Represents the weighted average sales price per share. The shares sold at prices ranging from $205.37 to $206.34 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 7 · 2026-10-05 · Sale · Disposed 146 · Balance 562,805 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F8: Represents the weighted average sales price per share. The shares sold at prices ranging from $206.38 to $207.33 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 8 · 2026-10-05 · Sale · Disposed 45 · Balance 562,760 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F9: Represents the weighted average sales price per share. The shares sold at prices ranging from $207.38 to $207.8 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.33 · Expires 2029-10-23 | Direct | 131,290 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 131,290 F10: 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $67.85 · Expires 2030-08-31 | Direct | 64,950 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 64,950 F11: Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026.
F2: Represents the weighted average sales price per share. The shares sold at prices ranging from $200 to $200.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F3: Represents the weighted average sales price per share. The shares sold at prices ranging from $201 to $201.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F4: Represents the weighted average sales price per share. The shares sold at prices ranging from $202 to $202.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F5: Represents the weighted average sales price per share. The shares sold at prices ranging from $203.29 to $203.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F6: Represents the weighted average sales price per share. The shares sold at prices ranging from $204.33 to $205.32 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F7: Represents the weighted average sales price per share. The shares sold at prices ranging from $205.37 to $206.34 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F8: Represents the weighted average sales price per share. The shares sold at prices ranging from $206.38 to $207.33 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F9: Represents the weighted average sales price per share. The shares sold at prices ranging from $207.38 to $207.8 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F10: 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
F11: Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 04, 2020 Filed Sep 9, 2020 22:04 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 8,309 | $60.97 | $506,598.90 |
DisclosureSEC source: 0001214659-20-007755 · marketforms-49642.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 699,389 F1 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $60.48 to $61.43 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 01, 2020 Filed Sep 4, 2020 00:36 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 21,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-007680 · marketforms-49585.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 707,698 F1 · shares: Represents a restricted stock unit award ("RSU") of which 1/16th of the total number of RSUs vest on each quarterly anniversary of October 1, 2020, for a total vesting period of 48 months, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| September 01, 2020 Filed May 23, 2023 20:10 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantEmployee Stock Option (right to buy) · Derivative | 64,950 | $0.00 Strike: $67.85 | $0.00 |
DisclosureSEC source: 0001214659-23-007730 · marketforms-61598.xml · derivative · entry 6 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,950 Underlying: Common Stock · 64,950 shares Expires 2030-08-31 F6 · balance_after: Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 21:41 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 3,007 | $67.28 | $202,310.96 |
DisclosureSEC source: 0001214659-20-007446 · marketforms-49489.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 686,048 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| August 07, 2020 Filed Aug 11, 2020 20:26 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 400 | $71.01 | $28,404.00 |
DisclosureSEC source: 0001214659-20-006967 · marketforms-49426.xml · nonDerivative · entry 3 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 689,055 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 16,2019. Read SEC document |
| August 07, 2020 Filed Aug 11, 2020 20:26 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 7,018 | $70.46 | $494,482.67 |
DisclosureSEC source: 0001214659-20-006967 · marketforms-49426.xml · nonDerivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 689,455 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 16,2019. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $70.00 to $70.94 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 07, 2020 Filed Aug 11, 2020 20:26 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 6,582 | $69.42 | $456,899.40 |
DisclosureSEC source: 0001214659-20-006967 · marketforms-49426.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 696,473 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 16,2019. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $69.00 to $69.96 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 21:48 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 15,000 | $59.33 | $889,966.50 |
DisclosureSEC source: 0001214659-20-006470 · marketforms-49332.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 703,055 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 16,2019. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $59.00 to $59.86 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 10:44 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 200 | $52.24 | $10,448.00 |
DisclosureSEC source: 0001214659-20-006241 · marketforms-49206.xml · nonDerivative · entry 5 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 718,055 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 16,2019. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 10:44 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,883 | $51.60 | $97,165.81 |
DisclosureSEC source: 0001214659-20-006241 · marketforms-49206.xml · nonDerivative · entry 4 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 718,255 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 16,2019. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $51.17 to $52.15 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 10:44 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 9,430 | $50.51 | $476,266.87 |
DisclosureSEC source: 0001214659-20-006241 · marketforms-49206.xml · nonDerivative · entry 3 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 720,138 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 16,2019. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $50.16 to $51.14 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 10:44 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 8,187 | $49.89 | $408,408.50 |
DisclosureSEC source: 0001214659-20-006241 · marketforms-49206.xml · nonDerivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 729,568 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 16,2019. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $49.16 to $50.14 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| July 07, 2020 Filed Jul 10, 2020 10:44 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 300 | $49.00 | $14,700.00 |
DisclosureSEC source: 0001214659-20-006241 · marketforms-49206.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 737,755 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 16,2019. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 21:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 24,500 | $39.14 | $958,888.35 |
DisclosureSEC source: 0001214659-20-005368 · marketforms-48952.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 738,055 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 16,2019. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $39.00 to $39.57 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 26, 2020 Filed May 27, 2020 22:26 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 300 | $39.90 | $11,968.50 |
DisclosureSEC source: 0001214659-20-005094 · marketforms-48874.xml · nonDerivative · entry 5 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 762,555 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F6 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $39.75 to $40.025 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 26, 2020 Filed May 27, 2020 22:26 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,713 | $38.13 | $65,319.60 |
DisclosureSEC source: 0001214659-20-005094 · marketforms-48874.xml · nonDerivative · entry 4 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 762,855 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F5 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $37.66 to $38.635 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 26, 2020 Filed May 27, 2020 22:26 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 8,580 | $39.22 | $336,539.35 |
DisclosureSEC source: 0001214659-20-005094 · marketforms-48874.xml · nonDerivative · entry 3 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 764,568 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $38.66 to $39.58 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 22, 2020 Filed May 27, 2020 22:26 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,603 | $39.69 | $63,624.99 |
DisclosureSEC source: 0001214659-20-005094 · marketforms-48874.xml · nonDerivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 773,148 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $39.52 to $39.75 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 22, 2020 Filed May 27, 2020 22:26 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 12,910 | $39.22 | $506,297.93 |
DisclosureSEC source: 0001214659-20-005094 · marketforms-48874.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 774,751 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $38.52 to $39.51 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 21, 2020 Filed May 23, 2020 01:07 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 8,238 | $39.90 | $328,691.26 |
DisclosureSEC source: 0001214659-20-004967 · marketforms-48847.xml · nonDerivative · entry 7 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 787,661 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F8 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $39.52 to $40.18 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 21, 2020 Filed May 23, 2020 01:07 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 5,700 | $39.17 | $223,272.42 |
DisclosureSEC source: 0001214659-20-004967 · marketforms-48847.xml · nonDerivative · entry 6 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 795,899 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F7 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $38.52 to $39.50 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 21, 2020 Filed May 23, 2020 01:07 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 500 | $37.78 | $18,888.75 |
DisclosureSEC source: 0001214659-20-004967 · marketforms-48847.xml · nonDerivative · entry 5 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 801,599 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F6 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $37.51 to $38.11 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 20, 2020 Filed May 23, 2020 01:07 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 3,007 | $39.76 | $119,558.32 |
DisclosureSEC source: 0001214659-20-004967 · marketforms-48847.xml · nonDerivative · entry 4 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 802,099 F5 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| May 20, 2020 Filed May 23, 2020 01:07 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 600 | $41.07 | $24,642.00 |
DisclosureSEC source: 0001214659-20-004967 · marketforms-48847.xml · nonDerivative · entry 3 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 805,106 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| May 20, 2020 Filed May 23, 2020 01:07 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 11,311 | $40.21 | $454,773.46 |
DisclosureSEC source: 0001214659-20-004967 · marketforms-48847.xml · nonDerivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 805,706 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $39.90 to $40.85 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 20, 2020 Filed May 23, 2020 01:07 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 29,045 | $39.54 | $1,148,395.73 |
DisclosureSEC source: 0001214659-20-004967 · marketforms-48847.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 817,017 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $38.90 to $39.89 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. F3 · balance_after: Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 20, 2020 Filed Feb 25, 2020 00:00 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 3,007 | $33.13 | $99,621.91 |
DisclosureSEC source: 0001214659-20-001756 · marketforms-47852.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 845,283 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| November 20, 2019 Filed Nov 21, 2019 23:33 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 7,901 | $22.85 | $180,537.85 |
DisclosureSEC source: 0001214659-19-007340 · marketforms-46373.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 848,290 Read SEC document |
| October 24, 2019 Filed Nov 6, 2019 02:27 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantEmployee Stock Option (right to buy) · Derivative | 131,290 | $0.00 Strike: $23.33 | $0.00 |
DisclosureSEC source: 0001209191-19-055410 · doc4.xml · derivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,290 Underlying: Common Stock · 131,290 shares Expires 2029-10-23 F3 · derivative.exercise_date: 25% of the shares subject to the option vest and become exercisable on October 24, 2020 and 1/48th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuing service through each vesting date. Read SEC document |
| October 24, 2019 Filed Nov 6, 2019 02:27 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 30,630 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-055410 · doc4.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 856,191 F1 · shares: Represents a restricted stock unit award (the "RSU Award") that vests in installments, with 25% of the shares subject to the RSU Award vesting on October 24, 2020 and 1/16th of the shares subject to the RSU Award vesting on each quarterly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. F2 · balance_after: Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| November 19, 2018 Filed Nov 21, 2018 22:44 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantEmployee Stock Option (right to buy) · Derivative | 266,539 | $0.00 Strike: $26.66 | $0.00 |
DisclosureSEC source: 0001209191-18-059800 · doc4.xml · derivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,539 Underlying: Common Stock · 266,539 shares Expires 2028-11-18 F2 · derivative.exercise_date: 12/60th of the shares subject to the option vest and become exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| November 19, 2018 Filed Nov 21, 2018 22:44 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 114,231 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-059800 · doc4.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 822,561 F1 · shares: Represents a restricted stock unit award (the "RSU Award") that vests in installments, with 12/60th of the shares subject to the RSU Award vesting on November 20, 2019 and 1/20th of the shares subject to the RSU Award vesting on each quarterly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.